|
Oct 19
|
Mesoblast Advances Cellular Medicines Amid FDA Hopes
|
|
Oct 10
|
ASX Growth Companies With High Insider Ownership In October 2024
|
|
Oct 9
|
3 ASX Growth Companies With Insider Ownership Up To 37%
|
|
Jul 23
|
FDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapy
|
|
Jul 23
|
FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
|
|
May 24
|
ASX Growth Companies With High Insider Ownership And Revenue Increases Up To 76%
|
|
May 23
|
ASX Growth Leaders With High Insider Ownership To Watch
|
|
Jan 31
|
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
|
|
Jan 19
|
Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
|
|
Dec 21
|
5 Stocks to Ride the Santa Claus Rally
|
|
Aug 31
|
Mesoblast Limited (NASDAQ:MESO) Q4 2023 Earnings Call Transcript
|
|
Aug 30
|
Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023
|
|
Aug 29
|
Mesoblast Financial Results and Corporate Update Webcast
|
|
Aug 25
|
Is Mesoblast Ltd (MESO) a Hidden Value Trap? Unpacking the Risks and Rewards
|
|
Aug 25
|
Decoding Mesoblast Ltd's Performance: A Deep Dive into the Metrics
|
|
Jun 27
|
Pleasing Signs As A Number Of Insiders Buy Mesoblast Stock
|
|
Apr 28
|
Appendix 4C Quarterly Activity Report
|